Cervical Cancer Diagnostics Market Growth Outlook Through 2024-2033

Overview and Scope

Cervical cancer is a type of squamous cell carcinoma that occurs in the cervix (the lower part of the uterus). The cervix cancer diagnostic devices are used to diagnose cancer that occurs in the cervix.

Sizing and Forecast

The cervical cancer diagnostics market size has grown strongly in recent years. It will grow from $8.89 billion in 2023 to $9.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increased awareness and screening programs, hpv vaccination, technological advancements, aging population.

The cervical cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $11.95 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing hpv-related cancers, emerging markets, molecular testing advances, telemedicine and remote screening. Major trends in the forecast period include hpv testing, liquid-based cytology, automation and digital pathology, screen-and-treat programs:.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-global-market-report

Segmentation & Regional Insights

The cervical cancer diagnostics market covered in this report is segmented –

1) By Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Other Diagnostic Tests

2) By Age Group: Below 21, Age between 21 to 29, Age between 30 to 65, Above 65

3) By End User: Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres, Diagnostic Centres

North America was the largest region in the cervical cancer diagnostics market in 2023 Asia-Pacific was the second largest region in the cervical cancer diagnostics market. The regions covered in the cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3285&type=smp

Major Driver Impacting Market Growth

The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. For instance, in August 2023, according to national cancer institute report, in 2021, 72.4% of women between the ages of 21 and 65 had completed a cervical cancer screening. The rising adoption of cervical cancer diagnostic tests and emphasis on early diagnosis propels the growth of the cervical cancer diagnostics market.

Key Industry Players

Major companies operating in the cervical cancer diagnostics market include Abbott Laboratories, Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Zilico Ltd., Guided Therapeutics Inc., Thermo Fisher Scientific Inc., Carl Zeiss AG, OncoHealth Corporation, Arbor Vita Corporation, Micromedic Technologies Ltd., Trovagene Inc., Roche Diagnostics, Nucleix Ltd., BGI Genomics Co. Ltd., Cepheid, Exact Sciences Corporation, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., PerkinElmer Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation

The cervical cancer diagnostics market report table of contents includes: